Stoke Therapeutics Surges Ahead: Q2 Highlights and Future Prospects

Stoke Therapeutics recently concluded its second quarter 2026 business update conference call, offering a comprehensive overview of the company's progress across various fronts. Key highlights from the presentation include the ongoing phase III EMPEROR study, which is making steady strides towards a data readout in Q3 2027.

The recent completion of enrollment for the EMPEROR study within 10 months speaks to the growing awareness and enthusiasm surrounding zorevunersen's potential to revolutionize Dravet syndrome treatment. Notably, no patients have discontinued treatment, underscoring the efficacy of this investigational medicine. As the company prepares to initiate its rolling NDA submission in Q1 2027, it has scheduled a pre-NDA meeting with the FDA later this year.

This meeting will serve as an opportunity for Stoke Therapeutics to further educate the agency on zorevunersen's long-term safety and efficacy using prior and ongoing analyses from phase I, II, and OLE studies. The data readout from EMPEROR is poised to support the completion of the company's NDA submission.

Additionally, Stoke Therapeutics has been advancing its pipeline opportunities, including STK-002 for autosomal dominant optic atrophy (ADOA). The phase I study recently completed dosing in the first cohort of patients and moved into a higher dose in a second cohort. This expansion of research efforts also encompasses new targets in haploinsufficient diseases, primarily focusing on CNS disorders given the company's expertise.

The appointment of Tom McCauley as Chief Scientific Officer marks another significant step forward for Stoke Therapeutics, solidifying its leadership team and guiding the next phase of platform expansion. The pro forma cash position of approximately $420 million supports the company's business investments, providing a runway through to potential U.S. launch of zorevunersen by early 2028.

Stoke Therapeutics remains committed to delivering data and completing regulatory and commercial readiness activities necessary for bringing zorevunersen to patients as quickly as possible. As execution becomes increasingly crucial, the company is poised to capitalize on its momentum and solidify its position in the biotech landscape."